ReviewCureus2025
The Impact of Liver Cirrhosis on Clinical Outcomes in Patients With Acute Pancreatitis: A Systematic Review and Meta-Analysis.
Review in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Chronic liver disease impacting the severity of acute pancreatitis: a detailed narrative review of the literature.Frontiers in gastroenterology (Lausanne, Switzerland) · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This systematic review and meta-analysis analyzed the impact of liver cirrhosis (LC) on clinical outcomes in patients hospitalized with acute pancreatitis (AP). We searched multiple databases, including PubMed, Embase, Web of Science, and the Cochrane Library from inception to April 26, 2025, and included studies comparing outcomes between AP patients with and without LC. From the 1,233 initially identified studies, eight retrospective studies with a pooled sample of 3,513,655 patients were included in the final analysis, with an LC prevalence of 2.90%. Meta-analysis revealed that AP patients with LC had significantly higher mortality risk compared to non-cirrhotic patients [risk ratio (RR): 2.09, 95% confidence interval (CI): 1.74-2.52], with considerable heterogeneity (I² = 66%). Subgroup analysis of studies reporting adjusted effect estimates confirmed this finding (RR: 1.94, 95% CI: 1.52-2.48) with lower heterogeneity (I² = 28%). Cirrhotic patients also experienced significantly more severe AP (RR: 2.79, 95% CI: 1.53-5.11) with no heterogeneity among studies (I² = 0%). However, analysis showed no significant difference in acute kidney injury (AKI) risk between cirrhotic and non-cirrhotic patients (RR: 1.09, 95% CI: 0.84-1.41). Our findings highlight the importance of early identification and vigilant monitoring of cirrhotic patients with AP, who may benefit from coordinated multidisciplinary care involving hepatologists, nephrologists, and infectious disease specialists. The limitations of the study include the retrospective design of all included studies, insufficient granularity for comprehensive subgroup analyses based on liver disease etiology or fibrosis stage, and inconsistent reporting of key clinical outcomes across studies. Future prospective research should address these limitations to better inform personalized management strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.